Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
ApexOnco Front Page
Recent articles
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Ideate-Lung02 goes on global clinical hold.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
No fewer than four ADCs with this target start human testing.
On a cross-trial basis varegacestat beats Ogsiveo.
